Logo image of NIVF

NEWGENIVF GROUP LTD-A (NIVF) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:NIVF - VGG0544E3032 - Common Stock

0.8 USD
-0.01 (-1.23%)
Last: 12/26/2025, 4:04:37 PM
Fundamental Rating

1

Overall NIVF gets a fundamental rating of 1 out of 10. We evaluated NIVF against 102 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of NIVF have multiple concerns. NIVF is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NIVF has reported negative net income.
NIVF had a negative operating cash flow in the past year.
NIVF Yearly Net Income VS EBIT VS OCF VS FCFNIVF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 -1M -2M

1.2 Ratios

NIVF has a Return On Assets of -3.22%. This is in the lower half of the industry: NIVF underperforms 61.76% of its industry peers.
Looking at the Return On Equity, with a value of -4.40%, NIVF is in line with its industry, outperforming 46.08% of the companies in the same industry.
Industry RankSector Rank
ROA -3.22%
ROE -4.4%
ROIC N/A
ROA(3y)-0.84%
ROA(5y)N/A
ROE(3y)-1.23%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NIVF Yearly ROA, ROE, ROICNIVF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 -2 -4 -6 -8

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NIVF so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NIVF Yearly Profit, Operating, Gross MarginsNIVF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, NIVF has about the same amount of shares outstanding.
Compared to 1 year ago, NIVF has a worse debt to assets ratio.
NIVF Yearly Shares OutstandingNIVF Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2K 4K 6K 8K 10K
NIVF Yearly Total Debt VS Total AssetsNIVF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 20M 40M 60M

2.2 Solvency

NIVF has an Altman-Z score of -0.77. This is a bad value and indicates that NIVF is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.77, NIVF is doing worse than 84.31% of the companies in the same industry.
A Debt/Equity ratio of 0.10 indicates that NIVF is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.10, NIVF is in the better half of the industry, outperforming 73.53% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -0.77
ROIC/WACCN/A
WACCN/A
NIVF Yearly LT Debt VS Equity VS FCFNIVF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 20M 40M 60M

2.3 Liquidity

NIVF has a Current Ratio of 0.02. This is a bad value and indicates that NIVF is not financially healthy enough and could expect problems in meeting its short term obligations.
NIVF's Current ratio of 0.02 is on the low side compared to the rest of the industry. NIVF is outperformed by 95.10% of its industry peers.
NIVF has a Quick Ratio of 0.02. This is a bad value and indicates that NIVF is not financially healthy enough and could expect problems in meeting its short term obligations.
NIVF has a Quick ratio of 0.02. This is amonst the worse of the industry: NIVF underperforms 95.10% of its industry peers.
Industry RankSector Rank
Current Ratio 0.02
Quick Ratio 0.02
NIVF Yearly Current Assets VS Current LiabilitesNIVF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 500K 1M 1.5M 2M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for NIVF have decreased strongly by -486.09% in the last year.
EPS 1Y (TTM)-486.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-591.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 16.84% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2Y35.5%
EPS Next 3Y28.45%
EPS Next 5Y16.84%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NIVF Yearly Revenue VS EstimatesNIVF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 50M 100M 150M 200M 250M
NIVF Yearly EPS VS EstimatesNIVF Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 0 10 -10 20 30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NIVF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NIVF Price Earnings VS Forward Price EarningsNIVF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NIVF Per share dataNIVF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60

4.3 Compensation for Growth

A more expensive valuation may be justified as NIVF's earnings are expected to grow with 28.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.5%
EPS Next 3Y28.45%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NIVF!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

NEWGENIVF GROUP LTD-A

NASDAQ:NIVF (12/26/2025, 4:04:37 PM)

0.8

-0.01 (-1.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.01%
Inst Owner Change0%
Ins Owners0.01%
Ins Owner Change0%
Market Cap1.06M
Revenue(TTM)N/A
Net Income(TTM)-685.50K
AnalystsN/A
Price Target76.5 (9462.5%)
Short Float %N/A
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)400%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.07
P/tB 0.07
EV/EBITDA N/A
EPS(TTM)-76.6
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.65
OCFYN/A
SpS0
BVpS11.82
TBVpS11.82
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -3.22%
ROE -4.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-0.84%
ROA(5y)N/A
ROE(3y)-1.23%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.02
Quick Ratio 0.02
Altman-Z -0.77
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-486.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-591.54%
EPS Next YN/A
EPS Next 2Y35.5%
EPS Next 3Y28.45%
EPS Next 5Y16.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-395.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-61.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.77%
OCF growth 3YN/A
OCF growth 5YN/A

NEWGENIVF GROUP LTD-A / NIVF FAQ

Can you provide the ChartMill fundamental rating for NEWGENIVF GROUP LTD-A?

ChartMill assigns a fundamental rating of 1 / 10 to NIVF.


Can you provide the valuation status for NEWGENIVF GROUP LTD-A?

ChartMill assigns a valuation rating of 1 / 10 to NEWGENIVF GROUP LTD-A (NIVF). This can be considered as Overvalued.


What is the profitability of NIVF stock?

NEWGENIVF GROUP LTD-A (NIVF) has a profitability rating of 0 / 10.